Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12
- 11 April 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (15) , 2923-2933
Abstract
Key Points: Therapeutic DCs stimulated via NK1R stimulate type 1–biased immunity.Keywords
This publication has 50 references indexed in Scilit:
- Mononuclear Phagocyte-Derived IL-10 Suppresses the Innate IL-12/IFN-γ Axis in Lung-Challenged Aged MiceThe Journal of Immunology, 2008
- Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulationCurrent Opinion in Pharmacology, 2008
- Taking dendritic cells into medicineNature, 2007
- Tolerogenic dendritic cells and the quest for transplant toleranceNature Reviews Immunology, 2007
- In Vivo Signaling through the Neurokinin 1 Receptor Favors Transgene Expression by Langerhans Cells and Promotes the Generation of Th1- and Tc1-Biased Immune ResponsesThe Journal of Immunology, 2007
- Polarized Type-1 Dendritic Cells (DC1) Producing High Levels of IL-12 Family Members Rescue Patient TH1-type Antimelanoma CD4+ T cell Responses In VitroJournal of Immunotherapy, 2007
- Conceptual development of the immune system as a sixth senseBrain, Behavior, and Immunity, 2007
- Neuroendocrine Regulation of Skin Dendritic CellsAnnals of the New York Academy of Sciences, 2006
- Neuropeptide Control Mechanisms in Cutaneous Biology: Physiological and Clinical SignificanceJournal of Investigative Dermatology, 2006
- Antimicrobial activity of Substance P and Neuropeptide Y against laboratory strains of bacteria and oral microorganismsJournal of Neuroimmunology, 2006